Effectiveness, Safety of Remicade’s Biosimilar, Inflectra, Confirmed in Phase 3 Trial

Effectiveness, Safety of Remicade’s Biosimilar, Inflectra, Confirmed in Phase 3 Trial
Switching Crohn’s disease patients from Remicade (infliximab) to its biosimilar Inflectra has no negative impact to treatment safety or effectiveness, a Phase 3 clinical trial shows. Pfizer and Celltrion Healthcare jointly presented those trial results at the 25th United European Gastroenterology (UEG) Week, Barcelona, Spain. A biosimilar is a medicine highly similar to another, already approved, medicine (the “reference medicine”). In

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

Leave a Comment

Your email address will not be published. Required fields are marked *